SRSD107 is a next-generation long-acting siRNA therapy designed to selectively inhibit coagulation factor XI (FXI). The FXI target plays a key role in pathological thrombosis but has minimal impact on normal hemostatic function. By targeting FXI, SRSD107 has the potential to reduce thrombotic events while significantly lowering the risk of bleeding, demonstrating therapeutic advantages over coagulation factor X activity (FXa) inhibitors. The potential indications for SRSD107 are broad, including atrial fibrillation, venous thromboembolism (VTE), cancer-associated thrombosis, end-stage renal disease patients undergoing hemodialysis, and major orthopedic surgery populations whose treatment options are limited due to bleeding risks.

Sirius Therapeutics Pipeline

Currently, SRSD107 has completed two Phase I clinical trials, showing good safety and tolerability after a single dose. The relevant research findings were presented at the 2025 American College of Cardiology (ACC) Annual Scientific Session and the 2024 American Society of Hematology (ASH) Annual Meeting. The Phase II clinical trial of SRSD107 is being initiated to evaluate its safety and efficacy in preventing venous thromboembolism (VTE) in patients undergoing knee replacement surgery. This study will provide clinical scientific evidence for confirming its anticoagulant clinical benefits and dose selection for subsequent pivotal trials.

Both parties will jointly advance the development of SRSD107 through a 50:50 cost and profit-sharing model. According to the agreement, CRISPR Therapeutics will be responsible for the commercialization of the product in the United States, while Sirius Therapeutics will oversee the Greater China market.